FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances ...

After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

Researchers find that disrupted circadian rhythms may impair gut regeneration and microbiome balance, heightening colon ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of ...

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination ...

AI model calculates a protein-based stemness index to predict tumor aggressiveness and treatment resistance. Proteomic-based ...

As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances ...

AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...

Researchers reviewed cases in which patients experienced severe skin toxicities in response to immunotherapy, and sought to identify the distinct natures of these toxicities.